First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, ...

Sometimes the unintended consequences of a treatment can seem worse than the disease. That's certainly the case for patients ...

Survival rates from small trial suggest that adding pazopanib to standard treatment for Ewing sarcoma in children may extend lives without adding severe toxicity.

Given the critical importance of endocytosis detection in ADC research and development, ACROBiosystems has designed an ...

L left-sided mCRC (n=8, confirmed and unconfirmed)– 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed ...

Compugen’s Unigen AI/ML platform drives the discovery of potentially novel checkpoints. Find out what nudges me to rate CGEN ...

Although lowering drug costs is one of the few issues uniting almost all Americans, the president has done little to ...

A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...

Globe Investor value reports provide a daily price target for more than 9,000 stocks on the TSX, Nasdaq, and NYSE. Used by Bay Street pros, advisors and Canadians who invest on their own, they help ...

Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (≥2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment The median duration of response ...

Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First ...

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics ...